Drug intelligence / Profile preview

Fuke Hongjindan Capsule

Development stage: Phase 3
Lead developer: Hunan Jiudian Pharmaceutical
Administration: Oral

Overview

Fuke Hongjindan Capsule is a Traditional Chinese Medicine (TCM) developed by Hunan Jiudian Pharmaceutical for the treatment of chronic pelvic pain associated with the sequelae of pelvic inflammatory disease (SPID). It is specifically indicated for patients presenting with the damp-heat and blood stasis syndrome (湿热瘀阻证). The drug is currently in Phase III clinical trials in China to evaluate its efficacy and safety in reducing pain and improving clinical symptoms in this patient population. As a TCM formulation, it likely utilizes a multi-component approach to clear heat, resolve dampness, and promote blood circulation to alleviate inflammation and pain in the pelvic cavity.

Brand names: Fuke Hongjindan Capsule
Other names: 妇科红金丹胶囊

Targets

IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Fuke Hongjindan Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuke Hongjindan Capsule.